Side effects in ALK mutant NSCLC treatment

Created using ChatSlide

This presentation offers a comprehensive exploration of ALK mutant non-small cell lung cancer (NSCLC). It delves into the intricacies of ALK mutations and their treatment landscape, highlighting challenges specific to lorlatinib, a key therapeutic agent. The focus is on understanding its distinct safety profile, common adverse events, and their subsequent impact on patient quality of life. Recent research findings shed light on managing hyperlipidemia and CNS effects, advocating for a...